Expand NTRA Menu
NTRA MENU

NTRA Latest Press Releases

-- April 11, 2024 --

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation Business Wire 8:00 AM

-- April 8, 2024 --

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients Business Wire 8:00 AM

-- April 5, 2024 --

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer Business Wire 7:00 AM

-- April 1, 2024 --

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer Business Wire 8:00 AM

-- March 18, 2024 --

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera in Stage II Colorectal Cancer Business Wire 7:00 AM

-- March 14, 2024 --

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease Business Wire 8:00 AM

-- March 12, 2024 --

Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers Business Wire 8:00 AM

-- March 7, 2024 --

Natera Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan Business Wire 8:00 AM

-- February 29, 2024 --

Natera to Participate in March Investor Conferences Business Wire 8:00 AM

-- February 28, 2024 --

Natera Reports Fourth Quarter and Full Year 2023 Financial Results Business Wire 4:05 PM

-- February 27, 2024 --

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests Business Wire 8:00 AM

-- February 26, 2024 --

Medicare Extends Coverage of Natera's Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer Business Wire 7:00 AM

-- February 20, 2024 --

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call Business Wire 8:00 AM

-- January 30, 2024 --

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 Globe Newswire 9:15 AM
New Publication Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer Business Wire 7:00 AM

-- January 29, 2024 --

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties Business Wire 7:00 AM

-- January 26, 2024 --

CareDx Issues Statement in Patent Infringement Case Business Wire 9:45 PM

-- January 25, 2024 --

Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies Business Wire 7:00 AM

-- January 22, 2024 --

Invitae Completes Sale of Reproductive Health Assets to Natera PRNewswire 7:00 AM
Natera Acquires Reproductive Health Assets from Invitae Business Wire 7:00 AM

-- January 18, 2024 --

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera's Clinical Utility in CRC Business Wire 8:00 AM

-- January 16, 2024 --

Natera Provides Update on Ravgen Trial Business Wire 5:17 PM

-- January 9, 2024 --

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues Business Wire 7:00 AM

-- December 29, 2023 --

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Business Wire 8:00 AM

-- December 27, 2023 --

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics' RaDaR Test Business Wire 11:48 PM

-- December 26, 2023 --

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Business Wire 9:00 PM

-- December 21, 2023 --

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA Business Wire 8:00 AM

-- December 11, 2023 --

Delaware Court Denies CareDx's Motion for Summary Judgment on Two Natera Patents Business Wire 12:50 PM

-- December 6, 2023 --

Natera Presents New Signatera MRD Data Across Breast Cancer Treatment Settings at SABCS 2023 Business Wire 8:30 AM